Protocol No
DAIICHI-DS3610-071
Staff Member
Deepak Kilari
Phase
I
Summary
The purpose of this trial is to learn more about a trial intervention called DS3610a. A trial intervention is a drug that is not approved for your disease. It is being studied to see if it is safe, and if your disease or medical condition improves while taking it.
DS3610a is a type of drug called an antibody drug conjugate (ADC). ADCs are designed to attach to tumor cells and deliver medicine that helps the immune system fight tumors, without harming healthy cells. DS3610a is expected to activate the body’s immune system to fight against tumors.
Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Status
OPEN TO ACCRUAL
Categories
Cancer,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Other Skin,
Other Respiratory,
Colorectal,
Pancreas/Liver,
Skin Cancers,
Other Gynecologic,
Other Gastrointestinal,
Ovary,
Prostate,
Thoracic Cancers,
Gastrointestinal Cancers,
Sarcoma,
Uterine,
Kidney,
Gynecologic Cancers,
Breast Cancers,
Eye/Orbital Cancers,
Head and Neck Cancers,
Other Urologic,
Endocrine Cancers,
Prostate and Urologic Cancers
ClinicalTrials.gov